Biotech in Germany Celebrates the Closing of a €300M Fund
High-Tech Gründerfonds (HTGF), a VC with a long track of biotech investments in Germany, has closed a new fund could benefit the country’s biotech scene.
High-Tech Gründerfonds is a German VC that provides seed funding to high-tech startups, including several in the biotech space. The firm has now announced the final closing of a third fund with a total of €316.5M.
This new fund has seen Boehringer Ingelheim and Bayer as investors, which could drive more life science investment from the fund. Boehringer and HTGF have already invested together. Both participated in the Series A round of Rigontec, a German RNA technology biotech that sold to MSD for up to €464M around a year later.
Since the first closing of this third fund last September, HTGF has invested in 22 companies, out of which three were in the healthcare space: Implandata Ophthalmic Products, Heartbeat Medical Solutions and Scipio Bioscience. In the past, HTGF has invested in multiple German biotechs over the years, including Cardior Therapeutics in the cardiovascular space, Tolerogenixx working in cell therapy, Atriva Therapeutics tackling the flu, and AMAL Therapeutics in oncology.
Image via ProStockStudio /Shutterstock